AU2010339841B2 - Compound suitable for the treatment of synucleopathies - Google Patents

Compound suitable for the treatment of synucleopathies Download PDF

Info

Publication number
AU2010339841B2
AU2010339841B2 AU2010339841A AU2010339841A AU2010339841B2 AU 2010339841 B2 AU2010339841 B2 AU 2010339841B2 AU 2010339841 A AU2010339841 A AU 2010339841A AU 2010339841 A AU2010339841 A AU 2010339841A AU 2010339841 B2 AU2010339841 B2 AU 2010339841B2
Authority
AU
Australia
Prior art keywords
compound
syn
compounds
salt
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010339841A
Other languages
English (en)
Other versions
AU2010339841A1 (en
Inventor
Eliezer Masliah
Edward M. Rockenstein
Igor Flint Tsigelny
Wolfgang Wrasidlo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuropore Therapies Inc
Original Assignee
Neuropore Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuropore Therapies Inc filed Critical Neuropore Therapies Inc
Publication of AU2010339841A1 publication Critical patent/AU2010339841A1/en
Application granted granted Critical
Publication of AU2010339841B2 publication Critical patent/AU2010339841B2/en
Priority to AU2014271313A priority Critical patent/AU2014271313A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2010339841A 2009-12-16 2010-12-16 Compound suitable for the treatment of synucleopathies Ceased AU2010339841B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014271313A AU2014271313A1 (en) 2009-12-16 2014-12-04 Compound suitable for the treatment of synucleopathies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28708209P 2009-12-16 2009-12-16
US61/287,082 2009-12-16
PCT/US2010/060862 WO2011084642A1 (en) 2009-12-16 2010-12-16 Compound suitable for the treatment of synucleopathies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014271313A Division AU2014271313A1 (en) 2009-12-16 2014-12-04 Compound suitable for the treatment of synucleopathies

Publications (2)

Publication Number Publication Date
AU2010339841A1 AU2010339841A1 (en) 2012-07-05
AU2010339841B2 true AU2010339841B2 (en) 2014-09-25

Family

ID=43629477

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010339841A Ceased AU2010339841B2 (en) 2009-12-16 2010-12-16 Compound suitable for the treatment of synucleopathies

Country Status (12)

Country Link
US (2) US8846682B2 (enExample)
EP (1) EP2513090A1 (enExample)
JP (2) JP5922031B2 (enExample)
KR (1) KR20120112548A (enExample)
CN (1) CN102725284A (enExample)
AU (1) AU2010339841B2 (enExample)
BR (1) BR112012014807A2 (enExample)
CA (1) CA2784744A1 (enExample)
MX (1) MX335989B (enExample)
NZ (1) NZ600449A (enExample)
RU (1) RU2012129882A (enExample)
WO (1) WO2011084642A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2830608B8 (en) * 2012-03-28 2020-01-15 UCB Biopharma SRL Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
US9284309B2 (en) * 2012-07-16 2016-03-15 Neuropore Therapies, Inc. Di- and tri-heteroaryl derivatives as inhibitors of protein aggregation
WO2014179303A1 (en) * 2013-04-29 2014-11-06 The General Hospital Corporation Amyloid precursor protein mrna blockers for treating down syndrome and alzheimer's disease
AU2015211119B2 (en) 2014-01-29 2019-05-30 Ucb Biopharma Sprl Heteroaryl amides as inhibitors of protein aggregation
CN104530013B (zh) * 2014-12-04 2016-06-29 中国农业大学 基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途
EP3328379B1 (en) * 2015-07-29 2021-07-28 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
AU2018213886A1 (en) * 2017-01-26 2019-07-25 UCB Biopharma SRL Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation
ES2882285T3 (es) * 2017-01-26 2021-12-01 Ucb Biopharma Sprl Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
KR20190112022A (ko) * 2017-01-26 2019-10-02 유씨비 바이오파마 에스피알엘 단백질 응집의 조절제로서의 바이사이클릭 비스-헤테로아릴 유도체
US12178805B2 (en) 2017-05-11 2024-12-31 Remynd N.V. Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders
WO2018206760A1 (en) 2017-05-11 2018-11-15 Remynd N.V. Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders
US20250074902A1 (en) * 2021-12-27 2025-03-06 Shanghai Jingxin Biomedical Co., Ltd. Fused bicyclic heteroaryl amide compound as protein aggregation inhibitor
TW202415651A (zh) 2022-07-29 2024-04-16 日商住友製藥股份有限公司 含氮飽和雜環衍生物
TW202412787A (zh) 2022-07-29 2024-04-01 日商住友製藥股份有限公司 2(1h)-吡啶亞胺衍生物
WO2024102758A2 (en) * 2022-11-08 2024-05-16 The General Hospital Corporation N-(n-aminoalkyl)phenanthridiunium series of chloride-sensitive fluorophores and methods of use thereof
WO2025002040A1 (zh) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054410A1 (en) * 2006-02-07 2009-02-26 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0726263A3 (en) 1995-02-08 1996-10-09 American Cyanamid Co Herbicides (1,3,4) oxadiazoles and thiadiazoles
US5591695A (en) 1995-02-08 1997-01-07 American Cyanamid Co. Herbicidal [1,3,4]oxadiazoles and thiadiazoles
WO1998027108A2 (en) 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. New amide compounds and their use as nitric oxide synthase inhibitors
US6096688A (en) 1996-12-27 2000-08-01 American Cyanamid Company Oxazole carboxamide herbicides
JP2007519753A (ja) 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
CA2580767A1 (en) * 2004-09-17 2006-03-30 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
KR101394245B1 (ko) * 2005-12-30 2014-05-14 에스케이바이오팜 주식회사 아이속사졸 유도체 및 이의 용도
EP2007373A4 (en) * 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc INHIBITION OF ALPHA SYNUCLEINE TOXICITY
US8163953B2 (en) * 2008-04-18 2012-04-24 University Of Connecticut Compounds for lysosomal modulation and methods of use
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054410A1 (en) * 2006-02-07 2009-02-26 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
US8846682B2 (en) 2014-09-30
NZ600449A (en) 2014-10-31
BR112012014807A2 (pt) 2017-06-27
RU2012129882A (ru) 2014-01-27
US20130035342A1 (en) 2013-02-07
KR20120112548A (ko) 2012-10-11
JP5922031B2 (ja) 2016-05-24
JP2013514980A (ja) 2013-05-02
JP2016074679A (ja) 2016-05-12
EP2513090A1 (en) 2012-10-24
CN102725284A (zh) 2012-10-10
US20140364610A1 (en) 2014-12-11
MX335989B (es) 2016-01-07
WO2011084642A1 (en) 2011-07-14
AU2010339841A1 (en) 2012-07-05
CA2784744A1 (en) 2011-07-14
MX2012006740A (es) 2012-09-07

Similar Documents

Publication Publication Date Title
AU2010339841B2 (en) Compound suitable for the treatment of synucleopathies
AU2007245625B2 (en) N- ( 2-thiazolyl) -amide derivatives as GSK-3 inhibitors
DK2649075T3 (en) SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS
AU2014279116B2 (en) Amino-triazine derivatives and pharmaceutical composition containing said derivatives
AU2017248556B2 (en) Thiadiazolidinediones as gsk-3 inhibitors
WO2010033360A1 (en) Methods of treating a botulinum toxin related condition in a subject
CA2955059A1 (en) Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death
TW202334148A (zh) 用於治療弗里德希氏共濟失調（ｆｒｉｅｄｒｅｉｃｈ＇ｓ ａｔａｘｉａ）之化合物及方法
AU2021226297B2 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US20250263412A1 (en) Non-hydroxamate hdac6 inhibitors and related methods of use
CN115477626B (zh) N-取代苯基磺酰胺类化合物及其用途
CA2527906A1 (en) Acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides and uses thereof
AU2014271313A1 (en) Compound suitable for the treatment of synucleopathies
CN116410184B (zh) 喹唑酮烯酮唑类化合物及其制备方法和应用
WO2019146739A1 (ja) ドーパミンｄ３受容体拮抗作用を有する縮環化合物
RU2852028C2 (ru) Кристаллическая форма ингибитора фосфодиэстеразы, способ ее получения и ее применение
JP2025511927A (ja) 環内結合カルボニル基を有するミトフシン活性化剤及びその使用方法
CN106660971A (zh) 用于神经退行性疾病和阿尔茨海默病的治疗中的用途的双重抑制剂化合物
WO2025155711A1 (en) Lrrk2 inhibitors and compositions and uses thereof
Lingala et al. Synthesis and Evaluation of new Ethyl N-[(Z)-(2-Oxo-5-Sulfamoyl-Indolin-3-Ylidene) Amino] Carbamate Derivatives for their Antimicrobial and Anti-inflammatory Activity
KR20250008052A (ko) Vhl 리간드로서의 벤조티아졸 화합물
EP2527323A1 (en) Urea carbonyl disulfide derivatives and their therapeutic uses

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired